Stock Track | Arcutis Biotherapeutics (ARQT) Soars 8.36% After Hours on Robust Q4 Earnings Beat and ZORYVE Sales Growth

Stock Track

Feb 26, 2025

Shares of Arcutis Biotherapeutics Inc. (ARQT) surged 8.36% in after-hours trading on Tuesday following the release of the company's strong fourth quarter 2024 financial results. The biopharmaceutical company's performance was driven by better-than-expected revenue and earnings, fueled by rapidly growing sales of its flagship product ZORYVE across multiple indications.

For the fourth quarter, Arcutis reported net product revenue of $69.4 million, a staggering 413% increase compared to the prior year quarter. Total revenues came in at $71.4 million, beating analysts' estimates of $60.16 million. On the profitability front, the company reported a loss of $0.09 per share, significantly better than the consensus estimate of a $0.24 loss.

The stellar results were underpinned by the company's robust commercial execution and strong demand for ZORYVE, a topical PDE4 inhibitor approved for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. ZORYVE is now the most prescribed branded non-steroidal topical treatment across these three major inflammatory skin conditions in the United States.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1133653011"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1133653011\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1133653011?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-26 05:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133653011","market":"us","top_or_hot":-1,"title":"Stock Track | Arcutis Biotherapeutics (ARQT) Soars 8.36% After Hours on Robust Q4 Earnings Beat and ZORYVE Sales Growth","media":"Stock Track","content":"<p>Shares of Arcutis Biotherapeutics Inc. (ARQT) surged 8.36% in after-hours trading on Tuesday following the release of the company's strong fourth quarter 2024 financial results. The biopharmaceutical company's performance was driven by better-than-expected revenue and earnings, fueled by rapidly growing sales of its flagship product ZORYVE across multiple indications.</p>\n\n<p>For the fourth quarter, Arcutis reported net product revenue of $69.4 million, a staggering 413% increase compared to the prior year quarter. Total revenues came in at $71.4 million, beating analysts' estimates of $60.16 million. On the profitability front, the company reported a loss of $0.09 per share, significantly better than the consensus estimate of a $0.24 loss.</p>\n\n<p>The stellar results were underpinned by the company's robust commercial execution and strong demand for ZORYVE, a topical PDE4 inhibitor approved for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. ZORYVE is now the most prescribed branded non-steroidal topical treatment across these three major inflammatory skin conditions in the United States.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arcutis Biotherapeutics (ARQT) Soars 8.36% After Hours on Robust Q4 Earnings Beat and ZORYVE Sales Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arcutis Biotherapeutics (ARQT) Soars 8.36% After Hours on Robust Q4 Earnings Beat and ZORYVE Sales Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-26 05:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Arcutis Biotherapeutics Inc. (ARQT) surged 8.36% in after-hours trading on Tuesday following the release of the company's strong fourth quarter 2024 financial results. The biopharmaceutical company's performance was driven by better-than-expected revenue and earnings, fueled by rapidly growing sales of its flagship product ZORYVE across multiple indications.</p>\n\n<p>For the fourth quarter, Arcutis reported net product revenue of $69.4 million, a staggering 413% increase compared to the prior year quarter. Total revenues came in at $71.4 million, beating analysts' estimates of $60.16 million. On the profitability front, the company reported a loss of $0.09 per share, significantly better than the consensus estimate of a $0.24 loss.</p>\n\n<p>The stellar results were underpinned by the company's robust commercial execution and strong demand for ZORYVE, a topical PDE4 inhibitor approved for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. ZORYVE is now the most prescribed branded non-steroidal topical treatment across these three major inflammatory skin conditions in the United States.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARQT","symbol_name":"Arcutis Biotherapeutics Inc.","start_time":0,"source_url":"","article_id":"1133653011","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133653011","pubTimestamp":1740519165,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Arcutis Biotherapeutics Inc.  surged 8.36% in after-hours trading on Tuesday following the release of the company's strong fourth quarter 2024 financial results. The biopharmaceutical company's performance was driven by better-than-expected revenue and earnings, fueled by rapidly growing sales of its flagship product ZORYVE across multiple indications.For the fourth quarter, Arcutis reported net product revenue of $69.4 million, a staggering 413% increase compared to the prior year qua","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARQT":"Arcutis Biotherapeutics Inc."},"translate_title":"Arcutis Biotherapeutics(ARQT)因第四季度盈利强劲增长和ZORYVE销售增长而盘后飙升8.36%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARQT":1},"content_text":"Shares of Arcutis Biotherapeutics Inc. (ARQT) surged 8.36% in after-hours trading on Tuesday following the release of the company's strong fourth quarter 2024 financial results. The biopharmaceutical company's performance was driven by better-than-expected revenue and earnings, fueled by rapidly growing sales of its flagship product ZORYVE across multiple indications.\nFor the fourth quarter, Arcutis reported net product revenue of $69.4 million, a staggering 413% increase compared to the prior year quarter. Total revenues came in at $71.4 million, beating analysts' estimates of $60.16 million. On the profitability front, the company reported a loss of $0.09 per share, significantly better than the consensus estimate of a $0.24 loss.\nThe stellar results were underpinned by the company's robust commercial execution and strong demand for ZORYVE, a topical PDE4 inhibitor approved for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. ZORYVE is now the most prescribed branded non-steroidal topical treatment across these three major inflammatory skin conditions in the United States.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}